Abstracts tagged "Biomarkers"

Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: L05 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Benjamin Hsu¹, Jennifer Visich ², Mark Genovese ³, Kimberly Walter ², Mahru An ⁴, Remi-Martin Laberge ⁴ and Jamie Dananberg ⁴, ¹Unity Biotechnology, Brisbane, ²Unity Biotechnology, Brisbane, California, ³Stanford University, Stanford, CA, ⁴Unity Biotechnology, Brisbane, CA
Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…
Abstract Number: L15 • 2019 ACR/ARP Annual Meeting
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
David Isenberg¹, Richard Furie ², Nicholas Jones ³, Pascal Guibord ⁴, Joshua Galanter ⁵, Chin Lee ³, Anna McGregor ³, Balazs Toth ³, Julie Rae ³, Olivia Hwang ³, Pedro Miranda ⁶, Viviane de Souza ⁷, Juan Jaller-Raad ⁸, Anna Maura Fernandes ⁹, Rodrigo Garcia Salinas ¹⁰, Leslie Chinn ³, Michael Townsend ¹¹, Alyssa Morimoto ³ and Katie Tuckwell ¹², ¹University College London, London, United Kingdom, ²Northwell Health, Great Neck, NY, ³Genentech, Inc., South San Francisco, California, ⁴Hoffmann-La Roche Limited, Mississauga, Canada, ⁵Genentech, Inc., SOUTH SAN FRANCISCO, ⁶Centro Estudios Reumatologicos, Santiago, Chile, ⁷Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, ⁸Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, ⁹Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, ¹⁰Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ¹¹Genentech, Inc., San Fransisco, ¹²Genentech, Inc., South San Francisco, CA
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…
Abstract Number: 1364 • 2019 ACR/ARP Annual Meeting
Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
Yael Ross¹, Madhavi Siddhanthi ², Lewis VanBrackle ³, David Carpenter ⁴, Aishwarya Rallabhandy ⁵ and Mohammad Kamran ², ¹WellStar Kennestone regional medical center, Atlanta, GA, ²WellStar Medical Group, Marietta, GA, ³Kennesaw State University, Kennesaw, ⁴WellStar Kennestone regional medical center, Marietta, ⁵High School, Marietta
Background/Purpose: The goal for treatment of RA is to obtain low disease activity for better outcomes. In order to achieve low disease activity, it is…
Abstract Number: 2405 • 2019 ACR/ARP Annual Meeting
Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis
Jian Chen ¹, Meng-shi Tang ², Li-chang Xu ³, Shu Li ², Yan Ge ², Jing Tian ², Xi Xie ², Jin-wei Chen ², Jin-feng Du ² and Fen Li¹, ¹Department of Rheumatology and Immunology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China, Changsha, ²Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, ³International Department of YALI High School, Changsha
Background/Purpose: Patients with rheumatoid arthritis (RA) usually receive triple therapy with methotrexate (MTX), leflunomide (LEF) and infliximab (IFX), but nearly one-third of them do not…
Abstract Number: 45 • 2019 ACR/ARP Annual Meeting
bDMARD-experienced Filgotinib-treated Patient Samples Exhibit a Partial Reversion to the Peripheral Molecular Profile of a Demographically Matched Healthy Population
Peter Taylor¹, Emon Elboudwarej ², Bryan Downie ³, Lene Vestergaard ², Jinfeng Liu ², Amer M. Mirza ² and Rachael Hawtin ², ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, CA, ³Gilead Sciences, Inc., Foster Citty, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
Abstract Number: 1392 • 2019 ACR/ARP Annual Meeting
The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes
Grigor Abelian¹, Sheng Gao ², Yash Gandhi ¹, Blisse Vakkalagadda ¹, Vidya Perera ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The purpose of this investigation was to characterize the relationship between systemic exposure of abatacept and measures of target engagement to further support dosing…
Abstract Number: 2417 • 2019 ACR/ARP Annual Meeting
A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
Xavier Mariette¹, Michele Bombardieri ², Ilias Alevizos ³, Rachel Moate ⁴, Barbara Sullivan ⁵, Ghaith Noaiseh ⁶, Marika Kvarnström ⁷, William Rees ³, Liangwei Wang ³ and Gabor Illei ³, ¹Université Paris-Sud, Paris, France, Paris, Centre, France, ²Queen Mary University of London, London, UK, London, United Kingdom, ³Viela Bio, Gaithersburg, MD, USA, Gaithersburg, MD, ⁴AstraZeneca, Cambridge, UK, Cambridge, United Kingdom, ⁵Amgen Inc., South San Francisco, CA, USA, South San Francisco, CA, ⁶University of Pittsburgh, PA, USA, Pittsburgh, PA, ⁷Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: The interaction of inducible T cell costimulatory ligand (ICOSL) and the ICOS receptor is key in the pathogenesis of primary Sjögren’s syndrome (pSS). MEDI5872…
Abstract Number: 530 • 2019 ACR/ARP Annual Meeting
Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay
Daniel Dairaghi¹, Karen Cox ¹, Stephen Ho ¹, Paul Klekotka ², Diane Phillips ¹, Jean Lim ³, Shweta Urva ¹ and Dipak Patel ², ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, San Diego, CA, ³Eli Lilly and Company, singapore, Singapore
Background/Purpose: LY2775240 is a potent and selective phosphodiesterase (PDE4) inhibitor being investigated as a potential treatment for inflammatory disorders, such as psoriasis. PDE4 is expressed…
Abstract Number: 1422 • 2019 ACR/ARP Annual Meeting
Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Sean Connolly ⁷, Kuan-Hsiang Gary Huang ⁷, Yedid Elbez ⁸, Sumanta Mukherjee ⁷ and Roy Fleischmann ⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…
Abstract Number: 2432 • 2019 ACR/ARP Annual Meeting
Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts
Saviana Gandolfo¹, Cinzia Fabro ¹, Serena Colafrancesco ², Francesco Carubbi ³, Francesco Ferro ⁴, Elena Bartoloni ⁵, Efstathia Kapsogeorgou ⁶, Andreas Goules ⁶, Luca Quartuccio ¹, Roberta Priori ², Alessia Alunno ⁵, Guido Valesini ², Roberto Giacomelli ³, Roberto Gerli ⁵, Chiara Baldini ⁴, Athanasios Tzioufas ⁶ and Salvatore De Vita ¹, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, Roma, Italy, ³Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy, L'Aquila, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁶Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been implicated in primary Sjögren’s syndrome (pSS) and related B-cell lymphoproliferation / lymphoma (NHL) by tissue studies on salivary…
Abstract Number: 534 • 2019 ACR/ARP Annual Meeting
CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis
Silvia Piantoni¹, Francesca Regola ², Laura Andreoli ³, Angela Tincani ³ and Paolo Airò ⁴, ¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ⁴UO Reumatologia e Immunologia Clinica, Spedali Civili di Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: CXCL13 chemokine, by interacting with CXCR5 receptor, attracts B-lymphocytes and CD4+CXCR5+ICOS+ follicular helper T-lymphocytes (THFs) in lymphoid follicles. In rheumatoid arthritis (RA) CXCL13 is…
Abstract Number: 1424 • 2019 ACR/ARP Annual Meeting
The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
Jane Buckner¹, Vivian Bykerk ², V. Michael Holers ³, S. Louis Bridges ⁴, William Rigby ⁵, Sheng Gao ⁶, Marleen Nys ⁷ and Neelanjana Ray ⁸, ¹Benaroya Research Institute, Seattle, WA, ²Hospital for Special Surgery, New York City, NY, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁴University of Alabama at Birmingham, Birmingham, ⁵Dartmouth-Hitchcock Medical Center, Lebanon, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁸Bristol-Myers Squibb, Princeton
Background/Purpose: Mechanistic differences between biologic DMARDs are poorly understood. Exploring these mechanisms includes assessing the role of HLA-DRB1 alleles containing the shared epitope (SE), which…
Abstract Number: 2558 • 2019 ACR/ARP Annual Meeting
Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616
R Andrea Fan¹, Janet Anderl ¹, Brian Tuch ², Darrin Bomba ¹, Niti Goel ³ and Christopher Kirk ¹, ¹Kezar Life Sciences, South San Francisco, CA, ²Kezar Life Sciences, south san francisco, ³Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: KZR-616 is a selective inhibitor of the immunoproteasome, the form of proteasome found predominantly in immune cells. In nonclinical studies, KZR-616 blocks acute production…
Abstract Number: 583 • 2019 ACR/ARP Annual Meeting
A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy
Signe Holm Nielsen¹, Anne Bay-Jensen ², Mikkel Østergaard ³, Anne Siebuhr ⁴, Morten Karsdal ⁵, inge Juul Sørensen ⁶, Ulrich Weber ⁷, Anne Gitte Loft ⁸, Gina Kollerup ⁹, Gorm Thamsborg ⁹, Ole Rintek Madsen ¹⁰, Jakob Møller ¹¹ and Susanne Juhl Pedersen ¹², ¹Nordic Bioscience/Technical University of Denmark, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁴Nordic Bioscience, Herlev, ⁵Nordic Bioscience, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁷Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sonderborg, Denmark, ⁸Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁹Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark, ¹⁰Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, ¹¹Department of Radiology, Herlev and Gentofte University Hospital, Herlev, Denmark, Copenhagen, Denmark, ¹²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Axial spondyloarthritis (AxSpa) is characterized by inflammation in the sacroiliac joints and spine and associated with extracellular matrix (ECM) remodelling of affected tissues. Type…

1
2
3
…
45
Next Page »